Skip to main content
PP

Perlara PBC

Perlara, PBC utilizes precision drug discovery methods, including model-agnostic drug repurposing and virtual consulting, to guide families and researchers in developing targeted treatments for rare diseases. The company addresses the complexity of finding effective therapies by providing expert-led Cure Guides™ that streamline the planning and development process.

Founded 201413700+ followers
Updated 4 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Families and researchers face significant challenges in navigating the complexities of rare disease treatment development, often lacking the expert guidance needed to identify and pursue effective therapies. The process of planning and executing research for rare diseases can be overwhelming and difficult to manage without specialized knowledge.

Solution

Perlara offers "Guided Cures," a virtual consulting service that connects families and researchers with experienced Cure Guides who provide expert-led support in developing targeted treatments for rare diseases. These Cure Guides, consisting of researchers and clinicians, share their expertise to guide a globally distributed research team through the planning and development of treatment paths. Perlara's approach includes modality-agnostic virtual consulting and model-agnostic drug repurposing services, facilitating the identification of potential treatments and streamlining the research process. By providing access to specialized knowledge and a collaborative research environment, Perlara empowers families and researchers to accelerate the development of effective therapies for rare genetic diseases.

Target Audience

Perlara's primary customers are families affected by rare diseases and researchers seeking guidance and support in developing targeted treatments.

Features

  • Virtual consulting services connecting families with expert Cure Guides
  • Guidance from researchers and clinicians experienced in rare disease treatment
  • Planning and development of innovative cure and treatment paths
  • Modality-agnostic virtual consulting
  • Model-agnostic drug repurposing services
  • Facilitation of globally distributed research teams
This profile is AI-generated and may contain inaccuracies.